Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Liabilities (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Total Liabilities readings, the most recent being $1.4 billion for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 22.09% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 22.09% increase, with the full-year FY2025 number at $1.4 billion, up 22.09% from a year prior.
  • Total Liabilities hit $1.4 billion in Q4 2025 for Neurocrine Biosciences, up from $1.3 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.4 billion in Q4 2025 to a low of $582.3 million in Q2 2022.
  • Median Total Liabilities over the past 5 years was $777.9 million (2023), compared with a mean of $870.0 million.
  • Biggest five-year swings in Total Liabilities: decreased 14.01% in 2022 and later surged 60.86% in 2024.
  • Neurocrine Biosciences' Total Liabilities stood at $698.5 million in 2021, then fell by 5.38% to $660.9 million in 2022, then skyrocketed by 54.24% to $1.0 billion in 2023, then rose by 10.75% to $1.1 billion in 2024, then increased by 22.09% to $1.4 billion in 2025.
  • The last three reported values for Total Liabilities were $1.4 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.